Table 1 Baseline characteristics of randomized clinical trials using SLT
From: Where does selective laser trabeculoplasty stand now? A review
Author, year | Design, location | Type of glaucoma | # eyes after SLT | Treatment in control arm | Mean follow-up (months) | Mean age (years) | SLT group baseline IOP (mmHg) | Control group baseline IOP (mmHg) | Characteristics SLT (extent, number spots, power) |
|---|---|---|---|---|---|---|---|---|---|
Lai, 2004 [22] | SC, China | POAG, OHT | 29 | medication (not specified) | 60 | 51.9 ± 14.7 | 26.8 ± 5.6 | 26.2 ± 4.2 | 360°, 100, 1.0 ± 0.1 mJ |
Nagar, 2005 [23] | MC, UK | POAG, OHT, PEX, PDS | 128 | medication (lat) | 10.3 | 63 | NA | NA | 90° (25–30 spots), 180° (48–53 spots), 360° (93–102 spots), 0.8-1.7 mJ |
Nagar, 2009 [24] | SC, UK | POAG, OHT | 20 | medication (lat) | 4–6 | 66.4 | 26.1 ± 4.0 | 22.8 ± 4.5 | 360°, 100 ± 5, 0.8–1.4 mJ |
Katz, 2012 [21] | MC, USA | POAG, OHT | 67 | medication (prost) | 6–12 | NA | 25.0 ± 2.2 (4–6 mth group), 24.5 ± 2.1 (9–12 mth group) | 24.5 ± 2.2 (4–6 mth group), 24.7 ± 2.4 (9–12 mth group) | 360°, 100, 0.8–1.2 mJ |
Bovell, 2011 [26] | SC, Canada | POAG, PEX, PDS, mix mech, others | 89 | ALT | 60 | 69.7 ± 10.52 | 23.8 ± 4.9 | 23.48 ± 4.21 | 180°, 50, 0.47–1.5 mJ |
Liu, 2012 [27] | SC, Canada | POAG, OHT, PEX, PDS, NTG, juv OAG, mix mech | 20 | ALT | 37 | 48.7 ± 9.4 | 19.1 ± 4.5 | 21.9 ± 4.4 | 180°, 45–55, 0.7–0.8 mJ |
Rosenfeld, 2012 [28] | SC, Israel | POAG, OHT, PEX, PDS | 22 | ALT | 12 | 71.95 | 25.36 ± 1.83 | 25.11 ± 2.16 | 180°, 50–70, 0.8–1.2 mJ |
Kent, 2013 [29] | MC, Canada | PEX | 37 | ALT | 6 | 72.9 ± 9.86 | 23.1 ± 4.22 | 25.2 ± 4.87 | 180°, 53 ± 3.75, 0.6 mJ |